GACP-Certified Cannabis Cultivators (Thailand)

Policy risk

Recriminalisation uncertainty

The 2024 recriminalisation push created market uncertainty that halted many private GACP certification investments. Until legislative clarity is established, private cultivators are unlikely to commit capital to GACP facility upgrades needed for pharmaceutical-grade supply.

Bottleneck

GMP processor capacity as binding constraint

GACP-certified cultivator supply exceeds available GMP-processor capacity in 2025–2026. Only GPO and one or two private processors hold EU GMP-equivalent certification needed for pharmaceutical export. Cultivator count is not the binding export constraint; processor GMP capacity is.

Export

Germany and Australia market access

Germany's Bundesinstitut fur Arzneimittel is the primary EU pharmaceutical cannabis import regulator; Australia's TGA controls the Australian pathway. Thai GACP cultivators must align documentation with EU GMP-equivalent standards and destination-country import protocols to access these high-value pharmaceutical export markets.

GACP certification framework

WHO GACP guidelines, adopted by the Thai FDA, require cultivators to document seed-to-harvest traceability, pesticide-residue testing, microbial contamination limits, and post-harvest drying and storage conditions. The certification is site-specific and non-transferable. Annual renewal requires physical inspection by Thai FDA inspectors, a bottleneck given limited inspector capacity.

Government-sector dominance

The Government Pharmaceutical Organization (GPO) operates the largest GACP-certified cannabis farms in Thailand, including sites in Khon Kaen and Chiang Rai established under the National Cannabis Policy Committee framework. GPO farms supply the medical-cannabis extract programme for public hospitals and are the primary source for pharmaceutical-grade product. University farms (Chiang Mai University, Mae Fah Luang University) serve research and smaller supply functions.

Private sector bottleneck

Private GACP cultivators face a two-stage barrier: Thai FDA certification (capital-intensive indoor or greenhouse facility) followed by processor-buyer contracting. With the 2024 recriminalisation push creating market uncertainty, many private operators halted GACP certification investments. The surviving private certified base is estimated at 30–80 farms, mostly in Chiang Mai and northern provinces.

Export pathway constraint

EU and Australian pharmaceutical markets require EU GMP-equivalent processing as well as GACP cultivation. Thailand’s export bottleneck is at the GMP processor level, not cultivator level — only GPO and one or two private processors hold EU GMP certification. GACP cultivator capacity is therefore not the binding constraint in 2025-2026; processor GMP is.